Targeting MDM2/TPSO (translocator protein) [119], MDM2/PKC (protein kinase C) [120], MDM2/NF-kB (nuclear factor-kappa B) [121], MDM2/Bcl-2 (B-cell lymphoma-2) [122] and MDM2/NFAT1 (nuclear factor of activated T-cells 1) [123] had good anti-tumor activity and had the potential to reduce the adverse reactions of MDM2 inhibitors. The gene discussed is NFATC1; the disease is neoplasm.